Evidence map›Paper›PMID 39060973›Full record

ArticleBMC microbiology2024

Emergence of heteroresistance to carbapenems in Gram-negative clinical isolates from two Egyptian hospitals.

Alaa G Al-Shebiny, Riham M Shawky, Mohamed Emara

Abstract read
In one paragraph

Article in BMC microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Heteroresistance to amikacin inMicrobiology spectrum · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alaa G Al-ShebinyFaculty of Pharmacy, Department of Microbiology and Immunology, Helwan University, P. O. Box: 11795, Ain-Helwan, Cairo, 01060564729, Egypt.
Riham M ShawkyFaculty of Pharmacy, Department of Microbiology and Immunology, Helwan University, P. O. Box: 11795, Ain-Helwan, Cairo, 01060564729, Egypt.
Mohamed EmaraFaculty of Pharmacy, Department of Microbiology and Immunology, Helwan University, P. O. Box: 11795, Ain-Helwan, Cairo, 01060564729, Egypt. mohamed_emara@pharm.helwan.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntimicrobial resistance is a global concern, linking bacterial genotype and phenotype. However, variability in antibiotic susceptibility within bacterial populations can lead to misclassification. Heteroresistance exemplifies this, where isolates have subpopulations less susceptible than the main population. This study explores heteroresistance in Gram-negative bacteria, distinguishing between carbapenem-sensitive isolates and stable heteroresistant isolates (SHIs).

methodsA total of 151 Gram-negative clinical isolates including Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Proteus mirabilis from various sources were included. Heteroresistant isolates and their stability were detected by disc-diffusion technique while genotypic analysis was carried out by PCR and efflux activity was assessed by ethidium bromide (EtBr)-agar cartwheel method.

resultsA total of 51 heteroresistant subpopulations were detected, producing 16 SHIs upon stability-detection. Amplified resistance genes and EtBr-agar cartwheel method showed a significant difference between resistant subpopulations and their corresponding-sensitive main populations.

conclusionGenotypic analysis confirmed that genetic mutation can lead to resistance development although the main populations were sensitive, thereby leading to treatment failure. This is a neglected issue which should be highly considered for better treatment outcomes.

Indexed as

Anti-Bacterial AgentsCarbapenemsGenotypeGram-Negative BacteriaGram-Negative Bacterial InfectionsMicrobial Sensitivity TestsDrug Resistance, BacterialDrug Resistance, Multiple, BacterialEgyptHospitalsHumansAnti-Bacterial AgentsCarbapenemsCarbapenemsGenotypeHeteroresistancePhenotypeSubpopulationsTreatment failure

Identifiers

PMID39060973
PMCPMC11282848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.